Simon Kraler

#ESCCongress 2025 #Global #Health 🇪🇸

Proud to be a #Social #Media #Ambassador for #Acute #Coronary #Syndromes & #CAD – sharing the latest science 🌍Excited to work w/ @drmilicaa @franciscojlk @rafavidalperez @liberale_luca and all other amazing colleagues👇

#CVHealthForAll❤️

🚨 Excited to share that our latest study on the role of inflammatory activation in endothelial cells during the infarct response is now published in Circulation Research!

Huge thanks to all co-authors—especially Lukas, Till, Simone, and Ariane—for driving this project forward.

Vascular (dys)function in the failing heart - Nature Reviews Cardiology Coronary and systemic vascular dysfunction contributes to the initiation and progression of heart failure (HF) with or without reduced ejection fraction and, vice versa, HF compromises vascular functi...

Member publication alert:

Vascular (dys)function in the failing heart

www.nature.com/articles/s41...

🚨 Now up
@escardio.bsky.social

Acute coronary syndromes: together w/
@dlbhattmd.bsky.social, C Mueller & P Libby we call for a precision medicine approach

🔹 Diverse mechanisms
🔹 Sex-specific differences
🔹 Shifting risk factor profiles
🔹 AI tools for personalised care

doi.org/10.1093/eurh...

Lepodisiran: an RNA Targeting Lipoprotein(a) (ALPACA trial) | NEJM YouTube video by NEJM Group

Lepodisiran is a long-acting small interfering RNA that blocks hepatic apolipoprotein(a) production. A new Quick Take video covers the ALPACA trial’s findings in patients with elevated lipoprotein(a).

🎥 Watch now: youtu.be/B0aH0O9Pk7Q

#MedSky #CardioSky